Truist raised its price target for Vericel to $65 from $52 and still recommends buying the stock.

VCEL · Vericel Corporation

The AI's read

The change shows Truist sees greater potential in Vericel's shares, and its continued Buy rating supports the same view. The report gives no new sales or profit figures, so the positive case rests on the analyst's view rather than fresh company results.